A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease

Joshua J. Solomon, Sonye Danoff, Felix Woodhead, Shelley Hurwitz, Rie Maurer, Ian Glaspole, Paul F. Dellaripa, Bibek Gooptu, Robert Vassallo, P. Gerald Cox, Kevin R. Flaherty, Huzaifa I. Adamali, Michael A. Gibbons, Lauren Troy, Ian Forrest, Joseph A. Lasky, Lisa G. Spencer, Jeffrey Golden, Mary Beth Scholand, Nazia Chaudhuri, Mark A. Perella, David Lynch, Daniel C. Chambers, Martin Kolb, Cathie Spino, Ganesh Raghu, Hilary Goldberg, Ivan O. Rosas, the TRAIL1 Network Investigators
doi: https://doi.org/10.1101/2022.04.01.22273270
Back to top
Posted April 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
Joshua J. Solomon, Sonye Danoff, Felix Woodhead, Shelley Hurwitz, Rie Maurer, Ian Glaspole, Paul F. Dellaripa, Bibek Gooptu, Robert Vassallo, P. Gerald Cox, Kevin R. Flaherty, Huzaifa I. Adamali, Michael A. Gibbons, Lauren Troy, Ian Forrest, Joseph A. Lasky, Lisa G. Spencer, Jeffrey Golden, Mary Beth Scholand, Nazia Chaudhuri, Mark A. Perella, David Lynch, Daniel C. Chambers, Martin Kolb, Cathie Spino, Ganesh Raghu, Hilary Goldberg, Ivan O. Rosas, the TRAIL1 Network Investigators
medRxiv 2022.04.01.22273270; doi: https://doi.org/10.1101/2022.04.01.22273270
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area